---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-006522"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:49:16.406099+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024

## Summary
- Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
- Trial at Medanta Medicity Hospital, Gurugram, India; Dr. Ashok K. Vaid and Dr. Puneet Sodhi as investigators.
- Patient recruitment expected Q4 2024; primary endpoint is safety, with exploratory EV reduction analyses.
- This adds to prior Australian ethics approvals and DCGI No Objection Certificate for the oncology trial.
- Hemopurifier designed to remove tumor-derived extracellular vesicles that may drive resistance to PD-1 inhibitors.

## SEC filing metadata
- accession: 0001683168-24-006522
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/0001683168-24-006522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-006522
- JSON: https://secwatch.observer/filing/0001683168-24-006522.json
- Plain text: https://secwatch.observer/filing/0001683168-24-006522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.